Retatrutide vs tirzepatide: what the evidence actually shows

Retatrutide has earned a reputation as the most powerful weight-loss drug yet reported — a reputation built almost entirely on a single number. In its Phase 2 obesity trial, the highest dose produced a mean weight reduction of roughly 24.2%, edging past tirzepatide's celebrated 20.9%.^[1][2] On paper, that looks like a clear winner. In practice, the comparison is far less settled than the headline suggests, and getting the caveats right matters more here than almost anywhere else in the GLP-1 conversation.

Why retatrutide might be more powerful: a third receptor

Tirzepatide is a dual agonist, activating the GLP-1 and GIP receptors. Retatrutide adds a third target: the glucagon receptor. Glucagon-receptor agonism is thought to increase energy expenditure and affect hepatic fat handling, on top of the appetite-suppressing and insulin-related effects of the GLP-1 and GIP arms. The mechanistic logic is genuinely appealing — a third lever that the dual agonist does not pull. But mechanism predicts direction, not magnitude, and it has never on its own settled a clinical question.

The numbers everyone compares — and why they don't line up

In the retatrutide Phase 2 obesity trial, 338 adults were randomized to retatrutide (up to 12 mg) or placebo for 48 weeks. The 12 mg group lost a least-squares mean of about 24.2% of body weight, versus 2.1% with placebo.^[1] In SURMOUNT-1, tirzepatide at 15 mg produced a mean reduction of about 20.9% over 72 weeks, versus 3.1% with placebo.^[2] The retatrutide figure is numerically larger — but it comes from a shorter trial, a smaller and separate population, and an earlier phase of development.

The bar chart highlights tirzepatide not because it lost the numbers race, but because it is the one drug a patient can actually be prescribed today — with a longer trial behind the figure. Reading the two bars as a contest would be a mistake: they answer different questions asked of different people over different timeframes.

The comparison at a glance

The single fact that settles the “which is better” debate

There is no head-to-head trial. No study has randomized patients to retatrutide versus tirzepatide. Every side-by-side figure you will see — including the one in this article — is a cross-trial estimate, the weakest form of comparison. Cross-trial numbers can be distorted by differences in baseline weight, trial length, dropout handling, and study population. They are suggestive, never decisive.

For context, retatrutide also posted strong results in a separate Phase 2 trial in people with type 2 diabetes, reinforcing that the triple-agonist mechanism is active across populations.^[3] But that, too, is early-phase data — encouraging, not confirmatory.

The honest bottom line

On the narrow question of peak reported weight loss, retatrutide's Phase 2 number is the largest yet published — and its triple-agonist mechanism gives a plausible reason why. But “largest number” is not “better drug.” Tirzepatide is approved, available, and supported by a longer pivotal trial; retatrutide is investigational, tested for less time, in fewer people, and never against tirzepatide directly. If retatrutide reaches the market with its current efficacy intact, this comparison will become a real clinical question. Until then, the only fully proven option here is tirzepatide.

For the mechanism behind retatrutide's third receptor, see our retatrutide Phase 2 evidence review. For how tirzepatide stacks up against the other approved GLP-1 drug, see tirzepatide vs semaglutide and Zepbound vs Wegovy. You can also line the drugs up side by side with our GLP-1 comparison tool.